In this webinar on May 27th, we will explore how signal peptide engineering is emerging as a powerful strategy to improve mRNA therapeutics.
July 2, 2026
Avenue Biosciences Expands Board of Directors with Appointment of Dr. Jens Vogel
January 12, 2026
Avenue Biosciences raises $5.7M to scale the first platform modulating the secretory pathway for enhanced therapeutic protein manufacturing
June 11, 2025
Avenue Biosciences Selected for 2025 BioTools Innovator Accelerator Program
May 20, 2025
Veli-Pekka Jaakola joins Avenue Biosciences as Chief Technology Officer
October 22, 2024
Avenue Biosciences Raises $2.5M Seed to Scale AI-Enhanced Protein Engineering
October 7, 2024
Avenue Biosciences Welcomes Industry Experts to Advisory Board for Market Insights and Focused Growth
Using signal peptides to enhance expression of de novo-designed proteins
In this blog, we examine how signal peptide engineering can address challenges in the expression of de novo-designed proteins.
Leveraging signal peptides for smarter mRNA design
Advances in high throughput signal peptide analysis and computational models are creating new possibilities for smarter mRNA design.
Signal peptides – a significantly underutilized element in protein engineering
Despite existing in hundreds of thousands and expressing significant diversity, signal peptides have largely remained unexplored in commercial protein engineering. This is a missed opportunity as almost all therapeutic proteins and mRNA therapies contain a signal peptide that can be engineered for optimized production and functionality.
Meet us at PEGS Europe 2024
PEGS Europe, a biologics technology conference will be held in Barcelona, on November 5-7. Join our talk on November 6 by CEO Tero-Pekka Alastalo on optimizing protein expression with signal peptides.